Literature DB >> 12393465

The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.

Rajani K Vangala1, Marion S Heiss-Neumann, Janki S Rangatia, Sheo M Singh, Claudia Schoch, Daniel G Tenen, Wolfgang Hiddemann, Gerhard Behre.   

Abstract

The transcription factor PU.1 plays a pivotal role in normal myeloid differentiation. PU.1(-/-) mice exhibit a complete block in myeloid differentiation. Heterozygous PU.1 mutations were reported in some patients with acute myeloid leukemia (AML), but not in AML with translocation t(8;21), which gives rise to the fusion gene AML1-ETO. Here we report a negative functional impact of AML1-ETO on the transcriptional activity of PU.1. AML1-ETO physically binds to PU.1 in t(8;21)(+) Kasumi-1 cells. AML1-ETO binds to the beta(3)beta(4) region in the DNA-binding domain of PU.1 and displaces the coactivator c-Jun from PU.1, thus down-regulating the transcriptional activity of PU.1. This physical interaction of AML1-ETO and PU.1 did not abolish the DNA-binding capacity of PU.1. AML1-ETO down-regulates the transactivation capacity of PU.1 in myeloid U937 cells, and the expression levels of PU.1 target genes in AML French-American-British (FAB) subtype M2 patients with t(8;21) were lower than in patients without t(8;21). Conditional expression of AML1-ETO causes proliferation in mouse bone marrow cells and inhibits antiproliferative function of PU.1. Overexpression of PU.1, however, differentiates AML1-ETO-expressing Kasumi-1 cells to the monocytic lineage. Thus, the function of PU.1 is down-regulated by AML1-ETO in t(8;21) myeloid leukemia, whereas overexpression of PU.1 restores normal differentiation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393465     DOI: 10.1182/blood-2002-04-1288

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  81 in total

1.  Reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARalpha.

Authors:  Matthew J Walter; John S Park; Rhonda E Ries; Steven K M Lau; Michael McLellan; Sara Jaeger; Richard K Wilson; Elaine R Mardis; Timothy J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-19       Impact factor: 11.205

Review 2.  Role of transcription factors C/EBPalpha and PU.1 in normal hematopoiesis and leukemia.

Authors:  Steffen Koschmieder; Frank Rosenbauer; Ulrich Steidl; Bronwyn M Owens; Daniel G Tenen
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

3.  AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2.

Authors:  Wei Wang; Sven Schwemmers; Elizabeth O Hexner; Heike L Pahl
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

4.  Reprogramming leukemia cells to terminal differentiation and growth arrest by RNA interference of PU.1.

Authors:  Michael Papetti; Arthur I Skoultchi
Journal:  Mol Cancer Res       Date:  2007-10       Impact factor: 5.852

5.  Ski can negatively regulates macrophage differentiation through its interaction with PU.1.

Authors:  N Ueki; L Zhang; M J Hayman; M J Haymann
Journal:  Oncogene       Date:  2007-07-09       Impact factor: 9.867

6.  Deletion of Mtg16, a target of t(16;21), alters hematopoietic progenitor cell proliferation and lineage allocation.

Authors:  Brenda J Chyla; Isabel Moreno-Miralles; Melissa A Steapleton; Mary Ann Thompson; Srividya Bhaskara; Michael Engel; Scott W Hiebert
Journal:  Mol Cell Biol       Date:  2008-08-18       Impact factor: 4.272

7.  Pharmacological inhibition of the transcription factor PU.1 in leukemia.

Authors:  Iléana Antony-Debré; Ananya Paul; Joana Leite; Kelly Mitchell; Hye Mi Kim; Luis A Carvajal; Tihomira I Todorova; Kenneth Huang; Arvind Kumar; Abdelbasset A Farahat; Boris Bartholdy; Swathi-Rao Narayanagari; Jiahao Chen; Alberto Ambesi-Impiombato; Adolfo A Ferrando; Ioannis Mantzaris; Evripidis Gavathiotis; Amit Verma; Britta Will; David W Boykin; W David Wilson; Gregory Mk Poon; Ulrich Steidl
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

Review 8.  Polycomb group proteins: navigators of lineage pathways led astray in cancer.

Authors:  Adrian P Bracken; Kristian Helin
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

Review 9.  Runx1/AML1 in normal and abnormal hematopoiesis.

Authors:  Tetsuya Yamagata; Kazuhiro Maki; Kinuko Mitani
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

10.  Driver mutations in Janus kinases in a mouse model of B-cell leukemia induced by deletion of PU.1 and Spi-B.

Authors:  Carolina R Batista; Michelle Lim; Anne-Sophie Laramée; Faisal Abu-Sardanah; Li S Xu; Rajon Hossain; Gillian I Bell; David A Hess; Rodney P DeKoter
Journal:  Blood Adv       Date:  2018-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.